Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 11, 2014, Pages 4161-4168

  Ross, Kathleen A ^a   Loyd, Hyelee ^b   Wu, Wuwei ^b   Huntimer, Lucas ^b   Wannemuehler, Michael J ^b   Carpenter, Susan ^b   Narasimhan, Balaji ^a  

^a Iowa State University of Science and Technology   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

H5N1; Hemagglutinin; Influenza; Nanoparticle; Polyanhydride; Vaccine

Indexed keywords

ANTIGENS; DEGRADATION; MONOCLONAL ANTIBODIES; OLIGOMERS; VACCINES;

1 ,6-BIS (P-CARBOXYPHENOXY)HEXANE; DEGRADATION PRODUCTS; H5N1; H5N1 AVIAN INFLUENZAS; HEMAGGLUTININ; INFLUENZA; POLYANHYDRIDES; PROTECTIVE IMMUNITIES;

NANOPARTICLES;

ACID ANHYDRIDE; AMPHOPHILE; HEXANE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYANHYDRIDE; POLYMER; TRIETHYLENE GLYCOL; 1,6-BIS(CARBOXYPHENOXY)HEXANE; DECANOIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION; DICARBOXYLIC ACID; RECOMBINANT PROTEIN; SEBACIC ACID;

ANTIGEN STRUCTURE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DEGRADATION KINETICS; DRUG FORMULATION; ENCAPSULATION; HYDROPHOBICITY; INFLUENZA VIRUS A H5N1; SYNTHESIS; CHEMISTRY; DELAYED RELEASE FORMULATION; HUMAN; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ANHYDRIDES; DECANOIC ACIDS; DELAYED-ACTION PREPARATIONS; DICARBOXYLIC ACIDS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEXANES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; NANOPARTICLES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 84908069924     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35086     Document Type: Article

References (38)

1. Gillim-Ross L, Subbarao K. Emerging respiratory viruses: Challenges and vaccine strategies. Clin Microbiol Rev 2006;19: 614-636.
2. World Lung Foundation. The Acute Respiratory Infections Atlas; 2010. http://www.ariatlas.org/. Accessed December 2012.
3. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009;83:5726-5734.
4. De Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-2672.
5. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. PNAS 2009;106:3455-3460.
6. Ou Q, Lu Y, Huang Q, Cheng X. Clinical analysis of 150 cases with the novel influenza A (H1N1) virus infection in Shanghai, China. Biosci Trends 2009;3:127-130.
7. Lazzari S, Stöhr K. Avian influenza and influenza pandemics. Bull World Health Organ 2004;82:242.
8. Cornelissen LAHM, de Vries RP, de Boer-Luijtze EA, Rigter A, Rottier PJM, de Haan CAM. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS ONE 2010;5: e10645.
9. Wei C-J, Xu L, Kong W-P, Shi W, Canis K, Stevens J, Yang ZY, Dell A, Haslam SM, Wilson IA, Nabel GJ. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from Avian H5N1 influenza virus. J Virol 2008;82:6200-6208.
10. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 2010;84:3201-3209.
11. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. Philadelphia: Mosby Elsevier; 2009.
12. Price GE, Soboleski MR, Lo C-Y, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009;27:6512-6521.
13. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009;27:2099-20107.
14. Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS ONE 2011;6:e17642.
15. Kipper MJ, Shen E, Determan AS, Narasimhan B. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. Biomaterials 2002;23:4405-4412.
16. Huntimer L, Wilson Welder JH, Ross K, Carrillo-Conde B, Pruisner L, Wang C, Narasimhan B, Wannemuehler MJ, Ramer-Tait AE. Single immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responses. J Biomed Mater Res B 2013; 101:91-98.
17. Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005;103:541-563.
18. Katti DS, Lakshmi S, Langer R, Laurencin CT. Toxicity, biodegradation and elimination of polyanhydrides. Adv Drug Deliver Rev 2002;54:933-961.
19. Manoharan C, Singh J. Evaluation of polyanhydride microspheres for basal insulin delivery: Effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo adsorption and bioactivity in diabetic rats. J Pharm Sci 2009;98: 4237-4250.
20. Griffin J, Delgado-Rivera R, Meiners S, Uhrich KE. Salicylic acidderived poly(anhydride-ester) electrospun fibers designed for regenerating the peripheral nervous system. J Biomed Mater Res A 2011;97:230-242.
21. Torres MP, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 2007;28:108-116.
22. Ross K, Loyd H, Wu W, Huntimer L, Ahmed S, Sambol A, Flickinger Z, Hinrichs S, Bronich T, Mallapragada S, Wannemuehler MJ, Carpenter S, Narasimhan B. Polyanhydridebased influenza HA nanovaccines elicit virus neutralizing titers and enhance cell-mediated immunity. Manuscript in preparation.
23. Conix A. Poly[1,3-bis(p-carboxyphenoxy)-propane anhydride]. Macro Synth 1966;2:95-98.
24. Torres MP, Vogel BM, Narasimhan B, Mallapragada SK. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms. J Biomed Mater Res Part A 2006;76A:102-110.
25. Shen E, Pizsczek R, Dziadul B, Narasimhan B. Microphase separation in bioerodible copolymers for drug delivery. Biomaterials 2001;22:201-210.
26. Determan AS, Trewyn BG, Lin VS, Nilsen-Hamilton M, Narasimhan B. Encapsulation, stabilization, and release of BSAFITC from polyanhydride microspheres. J Control Release 2004; 100:97-109.
27. Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J Virol Methods 2010; 165:305-310.
28. Tallmadge RL, Brindley MA, Salmans J, Mealey RH, Maury W, Carpenter S. Development and characterization of an equine infectious anemia Env-pseudotyped reporter virus. Clin Vaccine Immunol 2008;15:1138-1140.
29. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998;5:1481-1487.
30. Determan AS, Graham JR, Pfeiffer KA, Narasimhan B. The role of microsphere fabrication methods on the stability and release kinetics of ovalbumin encapsulated in polyanhydride microspheres. J Microencapsul 2006;23:832-843.
31. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 2000;69:531-569.
32. Lopac SK, Torres MP, Wilson-Welder JH, Wannemuehler MJ, Narasimhan B. Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres. J Biomed Mater Res B 2009;91B:938-947.
33. Luykx DMAM, Casteleijn MG, Jiskoot W, Westdijk J, Jongen PMJM. Physiochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 2004;23:65-75
34. Wharton SA, Ruigrok RWH, Martin SR, Skehel JJ, Bayley PM, Weist W, Wiley DC. Conformational aspects of the acid-induced fusion mechanism of influenza virus hemagglutinin. J Biol Chem 1988;263:4474-4480.
35. Determan AS, Wilson JH, Kipper MJ, Wannemuehler MJ, Narasimhan B. Protein stability in the presence of polymer degradation products: Consequences for controlled release formulations. Biomaterials 2006;27:3312-3320.
36. Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin S, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 2012;86:2978-2991.
37. Saluja V, Amorij J-P, Kapteyn JC, de Boer AH, Frijlink HW, Hinrichs WLJ. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release 2010;144:127-133.
38. Petersen LK, Phanse Y, Ramer-Tait AE, Wannemuehler MJ, Narasimhan B. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol Pharm 2012;9:874-882.